Relationship Between MMP-1, MMP-9, TIMP-1, IL-6 and Risk Factors, Clinical Presentation, Extent and Severity of Atherosclerotic Coronary Artery Disease by Tanindi, Asli et al.
110  The Open Cardiovascular Medicine Journal, 2011, 5, 110-116   
 
  1874-1924/11  2011 Bentham Open 
Open Access 
Relationship Between MMP-1, MMP-9, TIMP-1, IL-6 and Risk Factors, 
Clinical Presentation, Extent and Severity of Atherosclerotic Coronary 
Artery Disease 
Asli Tanindi
1,*, Asife Sahinarslan
1, Sehri Elbeg
2 and Mustafa Cemri
1 
1Gazi University Faculty of Medicine, Department of Cardiology, Turkey 
2Gazi University Faculty of Medicine, Department of Medical Biochemistry, Turkey 
Abstract: Background: Matrix metalloproteinases (MMPs) and Tissue Inhibitor of Matrix Metalloproteinases (TIMPs) 
may be associated with atherogenesis and plaque rupture. We evaluated the relationship between MMP-1, MMP-9, TIMP-
1 and IL-6 levels and risk factors, presentation, extent and severity of atherosclerotic coronary artery disease (CAD).  
Methods: Consecutive patients who underwent coronary angiography were randomly included. The serum concentrations 
of MMP-1, MMP-9, TIMP-1 and IL-6 were analyzed with ELISA method in 134 patients. Participants were divided into 5 
groups; stable angina pectoris (SAP; n= 34), unstable angina pectoris (USAP; n=29), non-ST elevation myocardial 
infarction (NSTEMI; n=16), acute ST elevation myocardial infarction (STEMI; n=25) and controls (n=30). Coronary 
angiographic Gensini score was calculated.  
Results: MMP-1 levels were higher in STEMI and NSTEMI groups compared with USAP, SAP and control groups 
(STEMI vs USAP p=0.005; STEMI vs SAP p=0.001; STEMI vs control p<0.001; NSTEMI vs USAP p=0.02; NSTEMI 
vs SAP p=0.027; NSTEMI vs control p<0.001). In STEMI group, MMP-9 levels were higher than USAP and control 
groups (p=0.002; p<0,001). TIMP-1 levels were not significantly different within all 5 groups. MMP-1 levels were found 
to be elevated in diabetic patients (p=0.020); whereas MMP-9 levels were higher in smokers (p=0.043). Higher MMP-1, 
MMP-9 and IL-6 levels were correlated with severe Left Anterior Descending artery (LAD) stenosis and higher 
angiographic Gensini Score (for severe LAD stenosis; r = 0.671, 0.363, 0.509 p<0.001; for Gensini score; r = 0.717, 
0.371, 0.578 p<0.001).  
Conclusions: Serum levels of MMP-1, MMP-9, and IL-6 are elevated in patients with CAD; more so in acute coronary 
syndromes. MMP-1, MMP-9 and IL-6 are associated with more extensive and severe CAD (as represented by Gensini 
score).  
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INTRODUCTION 
  Atheroma is no longer considered simply as lipid 
deposition on the coronary artery wall. Inflammation, rather 
than the severity of narrowing of the arterial lumen plays the 
pivotal role for thrombotic complications in coronary artery 
disease (CAD) [1].  
  Matrix metalloproteinases (MMPs) which are secreted 
mostly by inflammatory cells are members of a zinc-
dependant enzyme family which degrades extracellular 
matrix [2]. The disturbance of the physiologic balance 
between extracellular matrix production and degradation 
results in atherosclerosis in the cardiovascular system, 
stenosis in the coronary arteries, left ventricular hypertrophy 
and heart failure [3]. At least 23 structurally similar MMPs 
are defined. Although some MMPs are thought to have 
different effects on atherosclerotic plaque stability, the effect  
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for most MMPs, is the rupture of the coronary plaque by 
degrading the vascular extracellular matrix components. 
Global MMP activity is increased in highly inflammatory 
plaques [4]. It is also reported that the levels of MMP-1, 
MMP-3, MMP-8 and MMP-9 are increased in atheromatous, 
vulnerable plaques compared with fibrous plaques [1,5]. 
Angiogenesis which is well known to destabilize the plaque 
is also stimulated by MMPs [6].  
  However, some MMPs have a less known effect which is 
to increase plaque stability by stimulating the migration and 
proliferation of vascular smooth muscle cells from tunica 
media into tunica intima; thereby increasing the thickness of 
the atheromatous plaque [7]. MMP-2, MMP-9 and MMP-14 
degrades the basal membrane around the vascular smooth 
muscle cells and render these cells in contact with 
extracellular matrix. This interaction converts quiescent 
vascular smooth muscle cells into a proliferative and 
migratory form. The accumulation of vascular smooth 
muscle cells in the intima layer of the arterial wall is thought 
to stabilize plaques by increasing the thickness of the fibrous 
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  Results of the clinical studies about the levels of certain 
MMPs in stable and unstable coronary syndromes are 
inconsistent, especially for MMP-9.  
  Our aim was to investigate the serum levels of some 
selected MMPs in different coronary clinical presentations, 
in addition to identifying possible use of these molecules as 
predictors of CAD, severity and extent in stable and unstable 
cardiac disease. Therefore, we assessed the probable 
association between the serum levels of MMP-1, MMP-9, 
TIMP-1, IL-6 and Gensini score, an objective scoring system 
used to evaluate the extent and severity of CAD. 
MATERIAL AND METHODS 
   140 patients who admitted to the Cardiology 
Department of our university hospital between January and 
May 2009 with stable angina pectoris or acute coronary 
syndromes, and who were decided to undergo coronary 
angiography were consecutively included. The study was 
approved by the local Ethics committee. Written informed 
consent was obtained from each patient prior to 
participation. The study was completed with 134 patients 
due to the inadequate coronary angiographic view or 
unwillingness of the patient to participate. Since it would be 
unethical to perform coronary angiography for healthy 
individuals, the control group of the study consisted of the 
patients who were found to have normal coronary arteries 
within the study population. 
  Patients were divided into 4 groups. Group 1: Acute ST 
elevation myocardial infarction (STEMI) (n = 25); Group 2: 
Non-ST elevation myocardial infarction (NSTEMI) (n = 16); 
Group 3: Unstable angina pectoris (USAP) (n = 29); Group 
4: Stable angina pectoris (SAP) (n = 34); Control group: 
patients who had normal coronary arteries (n = 30). For the 
patients with unstable CAD (STEMI, NSTEMI, USAP),   
it was mandatory to undergo coronary angiography within 
the first 48 h of admission for inclusion. Exclusion criteria 
consisted of previous revascularisation, coronary angio- 
graphy after 48 h of hospital admission for patients with 
acute coronary syndromes, severe valvular disease, severe 
renal dysfunction (known renal failure and/or serum 
creatinin levels >1.6 mg/dL), severe hepatic dysfunction 
(known cirrhosis and or serum levels of AST, ALT, GGT > 
3 times of upper level), severe thyroid disease (increase or 
decrease in the levels of fT3, fT4 or TSH), malignant 
disorder (except for cured malignancies). 
  Demographic parameters, risk factors for atherosclerosis 
and past medical history were recorded for every participant. 
Blood samples were obtained for complete blood count, 
biochemistry/lipid parameters, and pro-Brain Natriuretic 
Peptide (pro-BNP) levels at admission. Electrocardiographic 
findings of all patients were recorded and every patient had 
an echocardiographic examination within 24 h of admission. 
Serum levels of creatine kinase (CK), creatine kinase 
myocardial isoenzyme (CKMB) and troponin T were 
recorded at the 72 nd hour of admission for patients who 
presented with acute coronary syndromes. Blood for MMP-
1, MMP-9, TIMP-1 and IL-6 was obtained through the 
femoral sheath which was placed into the femoral artery at 
the beginning of the coronary angiography procedure, 
centrifuged and kept at -70˚C thereafter. An ELISA 
(BenderMed System, Vienna, Austria) assay was used for 
the analysis of MMP and IL levels. Coronary angiography 
was performed using TOSHIBA Infinix CSI, and 6F 
catheters for all patients. Presence or absence of Left 
Anterior Descending coronary artery (LAD) disease with 
more than 70% stenosis and Gensini score for the extent and 
severity of coronary atherosclerosis were recorded for each 
patient. 
Statistical Analysis 
  SPSS for Windows 11.5 was used for the analysis of the 
data. Shapiro Wilk test was used to determine if the 
continuous variables were distributed close to normal. 
Descriptive statistics were shown as mean ± standart 
deviation or as medians for continuous variables; and as 
percentage of cases for categoric variables. 
  One-way ANOVA was used for evaluation of the 
significance of the difference between the groups in terms of 
means. Mann Whitney U test was used to evaluate the 
significance of difference between the groups in terms of 
medians when the number of groups was two; and Kruskal 
Wallis analysis was used when the number of groups was 
more than two. Categorical variables were evaluated by 
using Pearson’s Ki-square or Fischer’s exact ki-square test. 
Spearmen’s correlation test was used for the relationship 
between continuous variables. ROC analysis was used for 
the determination of the possible use of the markers for 
clinical differentiation between the case and the control 
groups. When the area under the curve was found to be 
significant, the cut-off values were determined and 
sensitivity and specificity for that particular cut-off point was 
calculated as well. 
RESULTS  
  Baseline characteristics of the patients are provided in 
Table 1. There were no differences between the groups in 
terms of height, weight, body mass index, history of 
hypertension, hyperlipidemia, family history for CAD, 
smoking habits or basal Hb levels. There was male 
predominance in the STEMI patients; whereas the 
percentage of females was higher in the SAP group. Number 
of diabetic patients were highest in the SAP group, followed 
by NSTEMI patients. Ischemic electrocardiographic findings 
were most frequent as expected in the STEMI group; and the 
ejection fractions of the patients in the STEMI and NSTEMI 
groups were lower than the others. Table 2 shows the mean 
serum levels of MMP-1, MMP-9, TIMP-1 and IL-6 in all 4 
patient groups and the controls. Number of patients who had 
metabolic syndrome were different among patient groups 
(Table  1); but no difference was observed in the marker 
levels with respect to the presence or absence of metabolic 
syndrome.  
MMP-1 
  MMP-1 levels were significantly higher in all coronary 
artery disease patients compared with the control group; and 
the patients who presented with STEMI or NSTEMI had 
higher levels of MMP-1 compared to USAP and SAP 
patients (STEMI vs USAP p = 0.005; STEMI vs SAP p = 
0.001; STEMI vs control p<0.001; NSTEMI vs USAP p = 
0.02; NSTEMI vs SAP p = 0.027; NSTEMI vs control 
p<0.001) (Fig. 1). Hypertensive status, family history of 
CAD and hyperlipidemia had no effect on the levels of the 112    The Open Cardiovascular Medicine Journal, 2011, Volume 5  Tanindi et al. 
Table 1.  Baseline Characteristics of the Study Population  
  Control 
N:30 
STEMI 
N:25 
NSTEMI 
N:16 
USAP 
N:29 
SAP 
N:34 
p 
Age  54.4±12.5 58.4±9.8  68.1±12.1 59.7±10.8 63.7±9.4  <0.001
* 
Gender (F/M)  17/13(56%)   5/20(20%)  9/7(56%)  9/20(31%)  14/20(41%)  0.017
** 
Weight  77.9±12.5 79.5±10.5 75.3±12.7 79.2±10.7 85.1±13.6 0.058 
Height  163.3±9.2 167.4±8.1 162.2±7.5 166.5±8.6 165.6±9.8 0.262 
BMI  29.4±5.2 28.4±3.4 28.7±5.2 28.6±4.1 31.2±5.7 0.146 
Met S   12 (40.0%)  13 (52.0%)  11 (68.8%)  13 (44.8%)  26 (76.5%)  0.021
*** 
HT  16 (53.3%)  10 (40.0%)  11 (68.8%)  13 (44.8%)  25 (73.5%)  0.051 
DM  6 (20.0%)  8 (32.0%)  6 (37.5%)  6 (20.7%)  17 (50.0%)  0.062 
Glu (mg/dL)  92(78-300)  126(80-270)  130(80-300)  96(58-161)  115(63-280)  <0.001
† 
FH  10 (33.3%)  11 (44.0%)  6 (37.5%)  9 (31.0%)  7 (20.6%)  0.414 
HPL  14 (46.7%)  11 (44.4%)  8 (50.0%)  13 (44.8%)  21 (61.8%)  0.612 
Smoking  10 (33.3%)  16 (64.0%)  7 (43.8%)  16 (55.2%)  14 (41.2%)  0.167 
EF (%)  67 (30-74)  42.5 (35-57)  47.5 (28-68)  66 (20-70)  66 (45-71)  <0.001
†† 
Hb  (g/dL)  14.1±1.1 14.2±1.6 13.5±1.9 14.2±1.8 14.2±1.2 0.487 
Ischemic ECG  7 (23%)  25 (100%)  8 (50%)  13 (44.8%)  6 (17.6%)  <0.001
‡ 
Basal characteristics of the study population. BMI: body mass index, Met S: metabolic syndrome, DM: diabetes mellitus, HT: hypertension, FH: family history of atherosclerotic 
coronary artery disease, EF: ejection fraction, Hb: hemoglobin, Glu: fasting blood glucose. For p values; *: control-Non ST Elevation MI (NSTEMI), **: ST Elevation MI (STEMI) - 
NSTEMI, ***:control-Stable Angina Pectoris (SAP), †:control-STEMI/NSTEMI, ††:control-STEMI/NSTEMI, ‡:control-STEMI/NSTEMI.  
Table 2.  Levels of Matrix Metalloproteinase-1 (MMP-1), Matrix Metalloproteinase-9 (MMP-9), Tissue Inhibitor of Matrix 
Metalloproteinase-1 (TIMP-1) and Interleukin-6 (IL-6) in Different Clinical Groups 
Marker Clinic N  Mean  Minimum  Maximum 
MMP-1 (ng/ml)  control 
STEMI 
NSTEMI 
USAP 
SAP 
Total 
30 
25 
16 
29 
34 
134 
0.989 
5.8232 
4.6969 
2.3224 
2.8668 
3.0987 
0.10 
0.08 
0.21 
0.28 
0.11 
0.08 
4.08 
13.60 
9.89 
11.87 
14.73 
14.73 
MMP-9 
(ng/ml) 
control 
STEMI 
NSTEMI 
USAP 
SAP 
Total 
30 
25 
16 
29 
34 
134 
175.16 
454.36 
284.43 
209.93 
291.67 
277.38 
52.0 
58.0 
52.0 
31.0 
52.0 
31.0 
431.0 
1500.0 
1008.0 
537.0 
1261.0 
1500.0 
IL-6 
(pg/ml) 
control 
STEMI 
NSTEMI 
USAP 
SAP 
Total 
30 
25 
16 
29 
34 
134 
1.81 
2.74 
2.96 
2.19 
2.13 
2.28 
1.55 
1.55 
1.64 
1.55 
1.55 
1.55 
2.88 
6.06 
6.93 
6.86 
7.01 
7.01 
TIMP-1 
(ng/ml) 
control 
STEMI 
NSTEMI 
USAP 
SAP 
Total 
30 
25 
16 
29 
34 
134 
527.79 
466.68 
478.88 
516.69 
551.69 
514.21 
177.20 
65.20 
44.0 
110.5 
111.10 
44.0 
953.00 
768.50 
720.70 
1212.80 
1280.00 
1280.00 Metalloproteinases and Coronary Artery Disease  The Open Cardiovascular Medicine Journal, 2011, Volume 5    113 
 
Fig. (1). Matrix Metalloproteinase-1 (MMP-1) levels according to patient groups. 
mentioned markers. Diabetic patients had significantly (p = 
0.02) higher levels of MMP-1. The mean MMP-1 level was 
2.79 ng/mL in non-diabetic patients (n = 91) and 3.75 ng/mL 
in the diabetic patients (n = 43). 
MMP-9 
  MMP-9 levels were highest in STEMI patients and this 
difference was significant when STEMI patients were 
compared with USAP and control group (p = 0.002; 
p<0.001). MMP-9 levels were higher in the smokers 
compared with non-smokers (p = 0.04). The mean MMP-9 
level was 245.7 ng/mL in non-smokers (n = 71) and 313.1 
ng/mL in smokers (n = 63).  
TIMP-1 
  TIMP-1 levels did not differ significantly but there was a 
trend towards lower values in the patients who had 
experienced myocardial infarction.  
IL-6 
  IL-6 levels were significantly different between groups as 
well (p<0.001). When compared with the control group, all 
patient groups except for the SAP patients had higher IL-6 
levels. In addition, when patient groups were compared 
within each other, STEMI and NSTEMI patients had 
significantly higher IL-6 levels than SAP group (p = 0.002; p 
= 0.005).  
Prediction of Coronary Artery Disease and nterrelations 
with other Biomarkers 
  Cut-off values for having CAD were calculated free from 
the presentation conditions. Table 3 shows the cut-off values, 
sensitivities and specificities of MMP-1, MMP-9 and IL-6 as 
predictors of CAD.  
  The serum levels of MMP-1, MMP-9, TIMP-1 and IL-6 
did not correlate with the levels of CK, CKMB or troponin T 
which were sampled at 72 h of admission in the STEMI and 
NSTEMI patients.  
  The pro-BNP levels were higher in STEMI and NSTEMI 
patients compared with USAP and SAP groups (STEMI vs 
USAP p = 0.011; STEMI vs SAP p = 0.002; NSTEMI vs 
USAP p<0.001; NSTEMI vs SAP p<0.001). There was a 
weak but significant correlation between pro-BNP and 
MMP-1 levels (correlation coefficient: 0.37; p<0.001) which 
continued to exist after statistical correction (ejection 
fraction, age and hypertension) had been conducted for the 
patient group, (B = 0.11 %95 CI:0.17-0.20). 
Extent and Severity of Coronary Artery Disease 
  There was a significant positive correlation between 
MMP-1, MMP-9 and IL-6 levels and the Gensini score; 
whereas such a correlation was not shown for TIMP-1. 
Patients who had severe stenosis in the LAD also had higher 
levels of MMP-1, MMP-9 and IL-6. Table 4 shows the 
correlation coefficients for each of the markers that have 
been shown to be related with Gensini score and the 
presence of severe LAD disease.  
  When statistical regression analysis was conducted to 
reveal any potential confounding effect of diabetes, 
hypertension, hyperlipidemia and the admission diagnosis of 
the patient on Gensini score or presence of severe LAD 
stenosis; the significant relation between MMP-1 and IL-6 
were found to persist (For Gensini score B = 0.124 %95 CI: 
0.75-0.174; B = 0.217 %95 CI:0.089-0.346; for severe LAD 
disease B = 0.059 %95 CI:0.031-0.086; B = 0.097 %95 
CI:0.025-0.169). 
DISCUSSION 
  We found that MMP-1 levels were higher in the patients 
with CAD compared with the patients with normal coronary 
arteries on coronary angiography. In addition MMP-1 levels 
were elevated to a higher degree in the subgroup of patients 114    The Open Cardiovascular Medicine Journal, 2011, Volume 5  Tanindi et al. 
who presented with acute coronary syndromes and high 
serum troponin. Similarly, MMP-9 levels were highest in the 
STEMI patients. The degree of elevation of MMP-1 and 
MMP-9 levels before coronary angiography correlated with 
the clinical condition that the patients presented with. Our 
findings are in concordance  with the results of some 
histological studies [1,5] which reported that MMP-1, MMP-
9, MMP-3 and MMP-8 levels were higher in unstable, 
vulnerable plaques compared with fibrous, stable plaques; 
and a clinical study which reported higher MMP-9 levels in 
the blood sample taken from culprit coronary vessel of 
STEMI patients compared with blood samples from 
peripheral vessels of the same patients [9]. 
  Inflammation has been accepted to play a role at all 
stages of atherosclerotic CAD including rupture of the 
plaque [10]. Our findings about serum IL-6 levels were 
concordant with some studies reporting IL-6 elevation in 
acute coronary syndromes. What we add is that; MMP-1 and 
MMP-9 were elevated in the same patient groups as IL-6. 
  TIMP-1, as a tissue inhibitor of MMPs, was expected to 
be lower in acute coronary syndromes. However, the results 
did not reach statistical significance but there was a trend 
towards lower TIMP-1 levels in STEMI and NSTEMI 
patients. 
  We provide potential cut-off values for CAD. Although 
the sensitivities are not so good; the specificities of these 
molecules as predictors of CAD are better (Sensitivities for 
MMP-1, MMP-9, IL-6 were 57%, 72%, 46%; specificities 
were 93%, 63%, 86% respectively). We conclude that MMP-
1, MMP-9 and IL-6 levels alone or in combination may 
prove useful to exclude CAD. 
  Smoking which is a strong risk factor for CAD by 
causing endothelial dysfunction, propensity for thrombosis 
and vasoconstriction [11], was associated with higher blood 
MMP-9 levels. MMP-9 is a MMP which acts not only in the 
plaque rupture stage but also in the initial stages where 
vascular smooth muscle migration to intima and proliferation 
takes place [12]. Depending on the the stage of 
atherosclerosis and the activity of other MMPs in the plaque, 
MMP-9 is thought to be capable of increasing plaque 
stability by increasing the thickness of the fibrous plaque 
instead of causing instability [13]. Percentage of smokers in 
different clinical groups were not significantly different in 
the entire study population; and MMP-9 which has dual role 
in atherosclerosis were found to be elevated in the smoker 
study population regardless of the clinical presentation.  
  Diabetes is an equivalent of CAD and MMP-1 levels 
were found to be significantly higher in the diabetic 
subgroup. We were not able to analyze if the relationship we 
have reported between these MMPs, diabetes and smoking 
considering the entire study population also existed when 
only the control group was analyzed because of the small 
number of patients for such a statistical analysis. 
  Considering the success of these markers to predict 
unstable cardiac disease, we aimed to evaluate the extent of 
myocardial damage in STEMI or NSTEMI, but we failed to 
demonstrate a correlation between MMP-1 or MMP-9 with 
CK, CKMB and troponin T. A possible explanation could be 
the difference between the timing of blood sampling, which 
was the 72 nd hour of hospital admission for CK, CKMB 
and troponin T; and the beginning of the coronary 
angiography procedure for MMP-1, MMP-9 and IL-6. 
Although STEMI patients were immediately taken to the 
catheterisation laboratory and NSTEMI patients had 
undergone coronary angiography within 48 h of hospital 
admission, it was impossible to obtain the blood samples 
exactly at the same time from the beginning of the chest pain 
for each participant. After a while, MMPs are known to be 
released from the ischemic myocardium [14]. In addition, in 
the presence of ongoing inflammatory activity, peripheral 
monocytes may also serve as sources for MMPs [15]. Last 
but not least, enzyme levels may not reflect enzyme activity. 
Considering all of these factors, the lack of correlation 
between MMPs  and cardiac enzymes may be due to a 
technical inability to reveal a probable relation.  
Table 3.  Cut-off Values for Matrix Metalloproteinase-1 (MMP-1), Matrix Metalloproteinase-9 (MMP-9), Interleukin-6 (IL-6); for 
Coronary Artery Disease 
  Cut-Off  Sensitivity (%)  Specificity (%) 
MMP-1 (ng/ml)  >2.03  57  93 
MMP-9 (ng/ml)  >158  72  63 
IL-6 (pg/ml)  >1.97  46  86 
 
Table 4.  Correlation Coefficients of Matrix Metalloproteinase-1 (MMP-1), Matrix Metalloproteinase-9 (MMP-9) and Interleukin-
6 (IL-6) with Gensini Score and >70% LAD Stenosis 
 Gensini Score   >70% LAD Stenosis   
Correlation Coefficient  P  Correlation Coefficient  p 
MMP-1 0.717  <0.001  0.671 <0.001 
MMP-9 0.371  <0.001  0.363 <0.001 
IL-6 0.578 <0.001  0.509  <0.001 Metalloproteinases and Coronary Artery Disease  The Open Cardiovascular Medicine Journal, 2011, Volume 5    115 
  Pro-BNP, a natriuretic peptide used for the diagnosis of 
heart failure, is stimulated by the tension and stretch of 
cardiac walls [16,17]. During acute ischemic insult, it is 
mainly thought to be elevated due to ischemic myocardial 
wall strech [18]. Currently, human atherosclerotic plaques 
are also thought to express natriuretic peptides, and there   
are studies reporting pro-BNP elevation during acute 
coronary syndromes or percutaneous interventions [19]. As 
anticipated, we found that pro-BNP levels were higher in the 
STEMI or NSTEMI patients; and more importantly we were 
able to show a positive correlation between MMP-1 and pro-
BNP although weak. It is meaningful for MMP-1 to have 
positive relation with pro-BNP which is a widely used 
marker to indicate a worse clinical condition. 
  As previously mentioned, MMPs are also released from 
the infarcted myocardium after STEMI since they are 
responsible from left ventricular remodelling [20]. In some 
animal studies; MMP-2, MMP-3 and MMP-9 expression was 
identified around the infarcted tissue after myocardial 
infarction [21]. In another study, MMP levels were analyzed 
after STEMI on day 0, 7, 2nd week and at fourth week; and 
any relation between MMP levels and ejection fraction was 
investigated. At day 0, MMP levels were higher in STEMI 
patients compared with stable angina patients who were 
chosen as controls and the blood levels of MMP-1 tended to 
increase until the second week, where it peaked, then 
decreased. The patients with highest 2nd week and 4th week 
MMP-1 levels had lower ejection fraction values measured 
by echocardiography at the 4th week [22].  
  Our study may be critisized because higher MMP levels 
were expected in the low EF group; and the relationship 
between MMP-1 and pro-BNP reflected heart failure. But as 
we described in the method section; the blood samples were 
drawn immediately after hospital admission in the STEMI 
group and within 48 h in the NSTEMI group which means 
there was not enough time for ventricular remodelling. Since 
the blood samples were obtained quite early for all patients, 
MMP levels reflect plaque rupture, not ventricular 
remodelling or heart failure. In addition, the positive relation 
between MMP-1 and pro-BNP have continued to exist after 
statistical correction by regression analysis for ejection 
fraction were conducted. 
  There are a few studies which report the relation between 
MMP-1 levels and 2 or 3 vessel disease or complex coronary 
lesions [23]. We show that MMP-1, MMP-9, and IL-6 
correlated with severe LAD stenosis. In addition we reported 
that MMP-1, MMP-9 and IL-6 were correlated with Gensini 
score which provides an objective estimation for the extent 
and severity of CAD. The relation have persisted for MMP-1 
and IL-6 after correction for probable confounders. As far as 
we know, this is the first study which relates Gensini score 
with any of MMPs. This relation is promising in predicting 
the extent and severity of CAD. 
  The major limitation was the timing of blood sampling. 
We tried to overcome this problem by including only the 
patients who were taken to catheter laboratory for coronary 
angiography within 48 h of hospital admission and excluding 
those patients whose coronary angiography was delayed for 
more than 48 h as described in the method section. Still, it is 
practically impossible to fix the time of blood sampling for 
NSTEMI and USAP patients, since the time between the 
onset of the chest pain and hospital admission may differ. 
  In conclusion; blood levels of MMP-1, MMP-9, IL-6 
were elevated in patients with CAD; this elevation was more 
pronounced in acute coronary syndromes. Most strikingly, 
they correlated with higher angiographic Gensini score. 
These findings should encourage future research about using 
MMPs to predict presence, severity and extent of CAD. 
Larger studies combining objective coronary angiographic 
parameters and histologic findings may be suggestive of 
widespread use of MMPs as risk predictors.  
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